Treatment of advanced non–small-cell lung cancer in the elderly: Results of an international expert panel
C Gridelli, M Aapro, A Ardizzoni, L Balducci… - Journal of Clinical …, 2005 - ascopubs.org
The best treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC)
is still debated. To guide clinical management of these patients and suggest the priorities for …
is still debated. To guide clinical management of these patients and suggest the priorities for …
[HTML][HTML] Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review
R Feld, SS Sridhar, FA Shepherd, JA Mackay… - Journal of Thoracic …, 2006 - Elsevier
Introduction Inhibition of the epidermal growth factor receptor is a promising therapy in the
treatment of non-small cell lung cancer (NSCLC). In this systematic review, we evaluated the …
treatment of non-small cell lung cancer (NSCLC). In this systematic review, we evaluated the …
Neglected and underrepresented subpopulations: elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer
CJ Langer - Clinical lung cancer, 2006 - Elsevier
Elderly patients and those with performance status (PS) of 2 with non-small-cell lung cancer
(NSCLC) have been habitually underrepresented in clinical trials. Therapeutic neglect and …
(NSCLC) have been habitually underrepresented in clinical trials. Therapeutic neglect and …
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
M Di Maio, C Gridelli, N Normanno… - Journal of cellular …, 2005 - Wiley Online Library
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
have shown promising activity in patients with non‐small cell lung cancer (NSCLC). Gefitinib …
have shown promising activity in patients with non‐small cell lung cancer (NSCLC). Gefitinib …
[PDF][PDF] Biologická liečba u seniorov
M Wagnerová - Onkologie, 2010 - onkologiecs.cz
Viac ako 50% pacientov s malignitami je diagnostikovaných vo veku nad 65 rokov. Malígne
ochorenia u seniorov predstavujú často náročné medicínske a psychosociálne problémy …
ochorenia u seniorov predstavujú často náročné medicínske a psychosociálne problémy …
[PDF][PDF] Lung Cancer Group Cologne (LCGC)
AM Platz, LC Center, M Schwartzkopff - Lung Cancer, 2009 - researchgate.net
ERLOPET Page 1 LCGC_ERLOPET (V3.01 / 16.11.2009) Clinical Study Protocol (including
second substantial amendment [Amendment 02, 16.11.2009]) ERLOPET Erlotinib and …
second substantial amendment [Amendment 02, 16.11.2009]) ERLOPET Erlotinib and …
Pneumotoxicity in therapy of NSCLC—from the point of view of a pneumologist
RM Huber, S Nährig - Der Onkologe, 2005 - Springer
Most therapeutic options for the treatment of NSCLC can cause toxic damage to lung tissue.
Pneumotoxicity is not only restricted to a hypersensitivity reaction or bronchospasm, it can …
Pneumotoxicity is not only restricted to a hypersensitivity reaction or bronchospasm, it can …
[PDF][PDF] NÁDORY PĽÚC V STARŠOM VEKU
M Wagnerová - Onkologie, 2007 - solen.cz
Karcinóm pľúc zaujíma popredné miesto v úmrtnosti ako v Európe, tak v USA. Medián veku v
čase diagnózy predstavuje 69 rokov a postupne sa zvyšuje so zmenou geriatrickej …
čase diagnózy predstavuje 69 rokov a postupne sa zvyšuje so zmenou geriatrickej …
[引用][C] 2004 Highlights From: 29th European Society of Medical Oncology Congress Vienna, Austria October 29 through November 2, 2004
GK Reddy, N Price, CP Belani - Clinical Lung Cancer, 2005 - infona.pl
2004 Highlights From: 29th European Society of Medical Oncology Congress Vienna, Austria
October 29 through November 2, 2004 × Close The Infona portal uses cookies, ie strings of …
October 29 through November 2, 2004 × Close The Infona portal uses cookies, ie strings of …